Scholarlink

Background <p>To develop a multimodal magnetic resonance imaging (MRI)-based spatial mapping framework for quantitatively characterizing intratumoral heterogeneity in recurrent glioblastoma (rGBM), identifying distinct imaging subregions, and classifying heterogeneity phenotypes predictive of treatment response and survival outcomes.</p> Methods <p>A total of 140 rGBM patients were recruited and underwent standardized diffusion-weighted imaging (DWI) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Pixel-wise colocalization of apparent diffusion coefficient (ADC) and DCE-MRI features identified four Multimodal Imaging Subregions (MIS). Entropy and Moran’s I quantified heterogeneity, and hierarchical clustering defined imaging phenotypes. Treatment response to 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), bevacizumab (Bev) + stereotactic radiotherapy (SRT), and Bev + CCNU was assessed by volumetric and component-level changes. Survival analyses were performed using Kaplan–Meier and multivariate Cox models.</p> Results <p>MIS4, defined by low ADC and slow-rising enhancement, was consistently treatment-resistant. Three imaging phenotypes with distinct heterogeneity patterns demonstrated significant prognostic stratification across regimens. Phenotype A showed the best outcomes under Bev-based regimens, while Phenotype B responded better to CCNU. Imaging phenotypes independently predicted progression-free survival (PFS) and overall survival (OS).</p> Conclusion <p>This framework enables spatially resolved, phenotype-based analysis of rGBM heterogeneity using routine MRI. Imaging phenotypes serve as non-invasive biomarkers to guide personalized treatment planning and outcome prediction in recurrent glioblastoma.</p> Clinical trial registration number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Heterogeneity phenotypes in recurrent glioblastoma: a multimodal MRI-based spatial mapping framework for precision treatment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月26日

查看全文
  • Yan Zhu,
  • Dian Huang,
  • Yang Ji,
  • Ranchao Wang,
  • Yang Li,
  • Yuhao Xu,
  • Yan Zhuang,
  • Zhe Liu,
  • Yuefeng Li,
  • Wei Wang

摘要

Background

To develop a multimodal magnetic resonance imaging (MRI)-based spatial mapping framework for quantitatively characterizing intratumoral heterogeneity in recurrent glioblastoma (rGBM), identifying distinct imaging subregions, and classifying heterogeneity phenotypes predictive of treatment response and survival outcomes.

Methods

A total of 140 rGBM patients were recruited and underwent standardized diffusion-weighted imaging (DWI) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Pixel-wise colocalization of apparent diffusion coefficient (ADC) and DCE-MRI features identified four Multimodal Imaging Subregions (MIS). Entropy and Moran’s I quantified heterogeneity, and hierarchical clustering defined imaging phenotypes. Treatment response to 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), bevacizumab (Bev) + stereotactic radiotherapy (SRT), and Bev + CCNU was assessed by volumetric and component-level changes. Survival analyses were performed using Kaplan–Meier and multivariate Cox models.

Results

MIS4, defined by low ADC and slow-rising enhancement, was consistently treatment-resistant. Three imaging phenotypes with distinct heterogeneity patterns demonstrated significant prognostic stratification across regimens. Phenotype A showed the best outcomes under Bev-based regimens, while Phenotype B responded better to CCNU. Imaging phenotypes independently predicted progression-free survival (PFS) and overall survival (OS).

Conclusion

This framework enables spatially resolved, phenotype-based analysis of rGBM heterogeneity using routine MRI. Imaging phenotypes serve as non-invasive biomarkers to guide personalized treatment planning and outcome prediction in recurrent glioblastoma.

Clinical trial registration number

Not applicable.